Effect of statin use on outcomes of non-muscle-invasive bladder cancer

BJU International

Volumn 112, Issue 2, 2013, Pages

  Crivelli, Joseph J ^a   Xylinas, Evanguelos ^a,c   Kluth, Luis A ^a,d   Da Silva, Rodrigo Donalisio ^a,e   Chrystal, James ^a   Novara, Giacomo ^f   Karakiewicz, Pierre I ^g   David, Scott G ^a   Scherr, Douglas S ^a   Lotan, Yair ^h   Shariat, Shahrokh F ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c Paris Descartes University ^*  (France)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

BCG; intravesical therapy; non muscle invasive bladder cancer; statin; urothelial carcinoma

Indexed keywords

BCG VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOMYCIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TRANSURETHRAL RESECTION; TRANSURETHRAL RESECTION OF THE BLADDER;

AGED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84879614726     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12150     Document Type: Article

References (26)

1. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 997-1008
2. Malmström P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus calmette-guérin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 247-256
3. Brandau S, Suttmann H,. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 2007; 61: 299-305
4. Bisiaux A, Thiounn N, Timsit M-O, et al. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer. J Urol 2009; 181: 1571-1580
5. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-guérin in intermediate- and high-risk ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013; 63: 462-472
6. Biot C, Rentsch CA, Gsponer JR, et al. Preexisting bcg-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med 2012; 4: 137ra72
7. Jain MK, Ridker PM,. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4: 977-987
8. McCarey DW, McInnes IB, Madhok R, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363: 2015-2021
9. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-1608
10. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J,. Statins in COPD: a systematic review. Chest 2009; 136: 734-743
11. Liakopoulos OJ, Kuhn EW, Slottosch I, Wassmer G, Wahlers T,. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev 2012; (4): CD008493
12. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110: 880-885
13. Greenwood J, Steinman L, Zamvil SS,. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6: 358-370
14. Tang T-T, Song Y, Ding Y-J, et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res 2011; 52: 1023-1032
15. Hoffmann P, Roumeguère T, Schulman C, van Velthoven R,. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 2006; 355: 2705-2707
16. Kamat AM, Wu X,. Statins and the effect of BCG on bladder cancer. N Engl J Med 2007; 356: 1276
17. Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM,. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. J Urol 2008; 180: 1297-1300; discussion 1300
18. Skolarus TA, Lee EW, Virgo KS, et al. Intravesical bacille calmette-guérin therapy for non-muscle-invasive bladder cancer: effects of concurrent statin therapy. J Am Coll Surg 2009; 209: 248-253
19. Nielsen SF, Nordestgaard BG, Bojesen SE,. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367: 1792-1802
20. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590
21. Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175, 000 people in 27 randomised trials of statin therapy. PLoS One 2012; 7: e29849
22. National comprehensive cancer network clinical practice guidelines in oncology: bladder cancer. 2013; Available at: http://www.nccn.org. Accessed December 2012
23. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus calmette-guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 2000; 163: 1124-1129
24. Rink M, Fajkovic H, Cha EK, et al. Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 2012; 61: 854-855
25. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166: 1842-1847
26. Colivicchi F, Bassi A, Santini M, Caltagirone C,. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007; 38: 2652-2657